Regulatory cells and human cancer

Seminars in Cancer Biology

Volumn 16, Issue 2, 2006, Pages 98-105

  Baecher Allan, Clare ^a   Anderson, David E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Human; Regulatory T cells; Tumor

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA;

CELL FUNCTION; CELL LINE; IMMUNOREGULATION; ONTOGENY; PHENOTYPE; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR IMMUNITY;

HUMANS; NEOPLASMS; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES, REGULATORY;

EID: 31644440643     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2005.11.003     Document Type: Review

References (94)

1. P. Ehrlich Ueber den jetzigen Stand der Karzinomforschung Ned Tijdschr Geneeskd 5 1909 273 290
2. W.B. Coley The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases Am J Med Sci 105 1893 487 511
3. L. Thomas Discussion H.S. In Lawrence Cellular and humoral aspects of the hypersensitive states 1959 Hoeber-Harper New York 529 532
4. M. Burnet Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications Br Med J 1957 841 847
5. M.L. Albert, and R.B. Darnell Paraneoplastic neurological degenerations: keys to tumour immunity Nat Rev Cancer 4 2004 36 44
6. M.V. Dhodapkar, J. Krasovsky, K. Osman, and M.D. Geller Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy J Exp Med 198 2003 1753 1757
7. G. Dranoff GM-CSF-based cancer vaccines Immunol Rev 188 2002 147 154
8. G.P. Dunn, L.J. Old, and R.D. Schreiber The immunobiology of cancer immunosurveillance and immunoediting Immunity 21 2004 137 148
9. M. Awwad, and R.J. North Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity J Exp Med 168 1988 2193 2206
10. M.J. Berendt, and R.J. North T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor J Exp Med 151 1980 69 80
11. S. Sakaguchi, K. Fukuma, K. Kuribayashi, and T. Masuda Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease J Exp Med 161 1985 72 87
12. M. Asano, M. Toda, N. Sakaguchi, and S. Sakaguchi Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation J Exp Med 184 1996 387 396
13. C. Baecher-Allan, V. Viglietta, and D.A. Hafler Human CD4+CD25+ regulatory T cells Semin Immunol 16 2004 89 98
14. C. Baecher-Allan, J.A. Brown, G.J. Freeman, and D.A. Hafler CD4+CD25high regulatory cells in human peripheral blood J Immunol 167 2001 1245 1253
15. D. Dieckmann, H. Plottner, S. Berchtold, T. Berger, and G. Schuler Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood J Exp Med 193 2001 1303 1310
16. L.S. Taams, J. Smith, M.H. Rustin, M. Salmon, L.W. Poulter, and A.N. Akbar Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population Eur J Immunol 31 2001 1122 1131
17. P.A. Taylor, R.J. Noelle, and B.R. Blazar CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade J Exp Med 193 2001 1311 1318
18. L.A. Stephens, C. Mottet, D. Mason, and F. Powrie Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro Eur J Immunol 31 2001 1247 1254
19. H. Jonuleit, E. Schmitt, M. Stassen, A. Tuettenberg, J. Knop, and A.H. Enk Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood J Exp Med 193 2001 1285 1294
20. R. Bacchetta, M. Bigler, J.L. Touraine, R. Parkman, P.A. Tovo, and J. Abrams High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells J Exp Med 179 1994 493 502
21. H. Groux, A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, and J.E. de Vries A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis Nature 389 1997 737 742
22. M. Stassen, E. Schmitt, and H. Jonuleit Human CD(4+)CD(25+) regulatory T cells and infectious tolerance Transplantation 77 2004 S23 S25
23. M.K. Levings, R. Sangregorio, C. Sartirana, A.L. Moschin, M. Battaglia, and P.C. Orban Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells J Exp Med 196 2002 1335 1346
24. G. Roncador, P.J. Brown, L. Maestre, S. Hue, J.L. Martinez-Torrecuadrada, and K.L. Ling Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level Eur J Immunol 35 2005 1681 1691
25. K. Wing, P. Larsson, K. Sandstrom, S.B. Lundin, E. Suri-Payer, and A. Rudin CD4+ CD25+ FOXP3+ regulatory T cells from human thymus and cord blood suppress antigen-specific T cell responses Immunology 115 2005 516 525
26. A. Fattorossi, A. Battaglia, G. Ferrandina, A. Buzzonetti, F. Legge, and V. Salutari Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients Gynecol Oncol 92 2004 106 115
27. M. Viguier, F. Lemaitre, O. Verola, M.S. Cho, G. Gorochov, and L. Dubertret Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells J Immunol 173 2004 1444 1453
28. H. Kawaida, K. Kono, A. Takahashi, H. Sugai, K. Mimura, and N. Miyagawa Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer J Surg Res 124 2005 151 157
29. R. Khattri, T. Cox, S.A. Yasayko, and F. Ramsdell An essential role for Scurfin in CD4+CD25+ T regulatory cells Nat Immunol 4 2003 337 342
30. J.D. Fontenot, M.A. Gavin, and A.Y. Rudensky Foxp3 programs the development and function of CD4+CD25+ regulatory T cells Nat Immunol 4 2003 330 336
31. S. Hori, T. Nomura, and S. Sakaguchi Control of regulatory T cell development by the transcription factor Foxp3 Science 299 2003 1057 1061
32. M.R. Walker, D.J. Kasprowicz, V.H. Gersuk, A. Benard, M. Van Landeghen, and J.H. Buckner Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells J Clin Invest 112 2003 1437 1443
33. T.J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, and P. Mottram Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 2004 942 949
34. L.A. Ormandy, T. Hillemann, H. Wedemeyer, M.P. Manns, T.F. Greten, and F. Korangy Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma Cancer Res 65 2005 2457 2464
35. C.P. Gray, P. Arosio, and P. Hersey Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma Clin Cancer Res 9 2003 2551 2559
36. E. Unitt, S.M. Rushbrook, A. Marshall, S. Davies, P. Gibbs, and L.S. Morris Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells Hepatology 41 2005 722 730
37. K. Noma, Y. Yamaguchi, R. Okita, K. Matsuura, and T. Toge The spleen plays an immunosuppressive role in patients with gastric cancer: involvement of CD62L+ cells and TGF-beta Anticancer Res 25 2005 643 649
38. U.K. Liyanage, T.T. Moore, H.G. Joo, Y. Tanaka, V. Herrmann, and G. Doherty Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma J Immunol 169 2002 2756 2761
39. F. Ichihara, K. Kono, A. Takahashi, H. Kawaida, H. Sugai, and H. Fujii Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers Clin Cancer Res 9 2003 4404 4408
40. M.S. Brady, D.D. Eckels, F. Lee, S.Y. Ree, and J.S. Lee Cytokine production by CD4+ T-cells responding to antigen presentation by melanoma cells Melanoma Res 9 1999 173 180
41. N.G. Chakraborty, L. Li, J.R. Sporn, S.H. Kurtzman, M.T. Ergin, and B. Mukherji Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines J Immunol 162 1999 5576 5583
42. T. Sasada, M. Kimura, Y. Yoshida, M. Kanai, and A. Takabayashi CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression Cancer 98 2003 1089 1099
43. B.C. Sheu, R.H. Lin, H.C. Lien, H.N. Ho, S.M. Hsu, and S.C. Huang Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer J Immunol 167 2001 2972 2978
44. T. Tatsumi, L.S. Kierstead, E. Ranieri, L. Gesualdo, F.P. Schena, and J.H. Finke Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma J Exp Med 196 2002 619 628
45. M.A. Morse, T.M. Clay, P. Mosca, and H.K. Lyerly Immunoregulatory T cells in cancer immunotherapy Expert Opin Biol Ther 2 2002 827 834
46. E.Y. Woo, C.S. Chu, T.J. Goletz, K. Schlienger, H. Yeh, and G. Coukos Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer Cancer Res 61 2001 4766 4772
47. E.Y. Woo, H. Yeh, C.S. Chu, K. Schlienger, R.G. Carroll, and J.L. Riley Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation J Immunol 168 2002 4272 4276
48. C. Schaefer, G.G. Kim, A. Albers, K. Hoermann, E.N. Myers, and T.L. Whiteside Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer Br J Cancer 92 2005 913 920
49. A.M. Wolf, D. Wolf, M. Steurer, G. Gastl, E. Gunsilius, and B. Grubeck-Loebenstein Increase of regulatory T cells in the peripheral blood of cancer patients Clin Cancer Res 9 2003 606 612
50. C.S. Hsieh, Y. Liang, A.J. Tyznik, S.G. Self, D. Liggitt, and A.Y. Rudensky Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors Immunity 21 2004 267 277
51. M.S. Jordan, A. Boesteanu, A.J. Reed, A.L. Petrone, A.E. Holenbeck, and M.A. Lerman Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide Nat Immunol 2 2001 301 306
52. H. Nishikawa, T. Kato, K. Tanida, A. Hiasa, I. Tawara, and H. Ikeda CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses Proc Natl Acad Sci USA 100 2003 10902 10906
53. H. Nishikawa, T. Kato, I. Tawara, T. Takemitsu, K. Saito, and L. Wang Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts Proc Natl Acad Sci USA 102 2005 9253 9257
54. H. Nishikawa, T. Kato, I. Tawara, K. Saito, H. Ikeda, and K. Kuribayashi Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells J Exp Med 201 2005 681 686
55. H.Y. Wang, G. Peng, Z. Guo, E.M. Shevach, and R.F. Wang Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells J Immunol 174 2005 2661 2670
56. H.Y. Wang, D.A. Lee, G. Peng, Z. Guo, Y. Li, and Y. Kiniwa Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy Immunity 20 2004 107 118
57. A. Iellem, M. Mariani, R. Lang, H. Recalde, P. Panina-Bordignon, and F. Sinigaglia Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells J Exp Med 194 2001 847 853
58. A.R. Dix, W.H. Brooks, T.L. Roszman, and L.A. Morford Immune defects observed in patients with primary malignant brain tumors J Neuroimmunol 100 1999 216 232
59. W.H. Brooks, M.G. Netsky, D.E. Normansell, and D.A. Horwitz Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor J Exp Med 136 1972 1631 1647
60. N.L. Levy Cell-mediated cytotoxicity and serum-mediated blocking: evidence that their associated determinants on human tumor cells are different J Immunol 121 1978 916 922
61. H.F. Young, R. Sakalas, and A.M. Kaplan Inhibition of cell-mediated immunity in patients with brain tumors Surg Neurol 5 1976 19 23
62. J.P. Zou, L.A. Morford, C. Chougnet, A.R. Dix, A.G. Brooks, and N. Torres Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers J Immunol 162 1999 4882 4892
63. A. Fontana, H. Hengartner, N. de Tribolet, and E. Weber Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects J Immunol 132 1984 1837 1844
64. T. Nitta, M. Hishii, K. Sato, and K. Okumura Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res 649 1994 122 128
65. M. Hishii, T. Nitta, H. Ishida, M. Ebato, A. Kurosu, and H. Yagita Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro Neurosurgery 37 1995 1160 1166 [discussion 1166-1167]
66. C. Huettner, S. Czub, S. Kerkau, W. Roggendorf, and J.C. Tonn Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro Anticancer Res 17 1997 3217 3224
67. M.K. Levings, R. Sangregorio, F. Galbiati, S. Squadrone, R. de Waal Malefyt, and M.G. Roncarolo IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells J Immunol 166 2001 5530 5539
68. M.G. Roncarolo, R. Bacchetta, C. Bordignon, S. Narula, and M.K. Levings Type 1 T regulatory cells Immunol Rev 182 2001 68 79
69. C.M. Ausiello, C. Palma, A. Maleci, G.C. Spagnoli, C. Amici, and G. Antonelli Cell mediated cytotoxicity and cytokine production in peripheral blood mononuclear cells of glioma patients Eur J Cancer 27 1991 646 650
70. L.H. Elliott, W.H. Brooks, and T.L. Roszman Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors J Immunol 132 1984 1208 1215
71. A. Cavani, F. Nasorri, C. Prezzi, S. Sebastiani, C. Albanesi, and G. Girolomoni Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses J Invest Dermatol 114 2000 295 302
72. A. Kitani, K. Chua, K. Nakamura, and W. Strober Activated self-MHC-reactive T cells have the cytokine phenotype of Th3/T regulatory cell 1 T cells J Immunol 165 2000 691 702
73. H. Jonuleit, E. Schmitt, H. Kakirman, M. Stassen, J. Knop, and A.H. Enk Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells J Exp Med 196 2002 255 260
74. S. Yamagiwa, J.D. Gray, S. Hashimoto, and D.A. Horwitz A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood J Immunol 166 2001 7282 7289
75. M. Platten, W. Wick, and M. Weller Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape Microsc Res Tech 52 2001 401 410
76. J. Satoguina, M. Mempel, J. Larbi, M. Badusche, C. Loliger, and O. Adjei Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis) Microbes Infect 4 2002 1291 1300
77. A.M. VanBuskirk, W.J. Burlingham, E. Jankowska-Gan, T. Chin, S. Kusaka, and F. Geissler Human allograft acceptance is associated with immune regulation J Clin Invest 106 2000 145 155
78. H. Jonuleit, E. Schmitt, G. Schuler, J. Knop, and A.H. Enk Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells J Exp Med 192 2000 1213 1222
79. M.V. Dhodapkar, R.M. Steinman, J. Krasovsky, C. Munz, and N. Bhardwaj Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells J Exp Med 193 2001 233 238
80. K. Steinbrink, H. Jonuleit, G. Muller, G. Schuler, J. Knop, and A.H. Enk Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells Blood 93 1999 1634 1642
81. F. Fiore, B. Nuschak, S. Peola, S. Mariani, M. Muraro, and M. Foglietta Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells Eur J Immunol 35 2005 1155 1163
82. T. Shono, P.J. Tofilon, J.M. Bruner, O. Owolabi, and F.F. Lang Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations Cancer Res 61 2001 4375 4381
83. T. Joki, O. Heese, D.C. Nikas, L. Bello, J. Zhang, and S.K. Kraeft Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398 Cancer Res 60 2000 4926 4931
84. S. Zha, V. Yegnasubramanian, W.G. Nelson, W.B. Isaacs, and A.M. De Marzo Cyclooxygenases in cancer: progress and perspective Cancer Lett 215 2004 1 20
85. Y. Akasaki, G. Liu, N.H. Chung, M. Ehtesham, K.L. Black, and J.S. Yu Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2- overexpressing glioma J Immunol 173 2004 4352 4359
86. S. Rutella, R.M. Lemoli, and Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications Immunol Lett 94 2004 11 26
87. M.A. Alyanakian, S. You, D. Damotte, C. Gouarin, A. Esling, and C. Garcia Diversity of regulatory CD4+T cells controlling distinct organ-specific autoimmune diseases Proc Natl Acad Sci USA 100 2003 15806 15811
88. N.G. Chakraborty, S. Chattopadhyay, S. Mehrotra, A. Chhabra, and B. Mukherji Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma Hum Immunol 65 2004 794 802
89. P. Yu, Y. Lee, W. Liu, T. Krausz, A. Chong, and H. Schreiber Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors J Exp Med 201 2005 779 791
90. T.M. Kuzel DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date Clin Lymphoma 1 Suppl. 1 2000 33 36
91. F.M. Foss DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma Clin Lymphoma 1 2000 110 116 [discussion 117]
92. H. Harizi, M. Juzan, V. Pitard, J.F. Moreau, and N. Gualde Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions J Immunol 168 2002 2255 2263
93. M. Stolina, S. Sharma, Y. Lin, M. Dohadwala, B. Gardner, and J. Luo Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis J Immunol 164 2000 361 370
94. F. Ghiringhelli, N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, and C. Garrido CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative Eur J Immunol 34 2004 336 344